• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Non-CNS patient outcomes treated via the NHS proton overseas programme

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Hwang, E. J.
    Gaito, S.
    France, A.
    Thwaites, D.
    Ahern, V.
    Indelicato, D.
    Smith, Ed
    Affiliation
    The Christie NHS Foundation Trust , Proton Beam Therapy, Manchester, United Kingdom
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Purpose or Objective The UK Proton Overseas Programme (POP) began in 2008, sending approved eligible patients abroad for proton beam therapy (PBT) funded by the National Health Service (NHS). POP patient outcomes data have been collected since 2008, now held Conclusion This large well-defined cohort of patients, diagnosed with non-CNS tumours undergoing multimodality therapy including PBT, demonstrates good local control, survival and acceptable toxicity rates, with some significant multivariate data analysis findings. in the Proton Clinical Outcomes Unit (PCOU) of The Christie NHS Foundation Trust. The POP will continue until the imminent second NHS centre is at full capacity. Outcomes are reported and analysed here for POP patients diagnosed with non central nervous system (non-CNS) tumours treated from 2008 to Sept 2020. Materials and Methods All non-CNS tumour files for treatments as of 30/09/2020 were interrogated for follow-up information (latest dates and status), and type (following CTCAE v4) and time of onset of any late (>90 days post-PBT completion) grade 3-5 toxicities. Where a patient’s available data was inadequate, their local UK follow-up centre was requested to update via a specific outcomes form. Univariate and multivariate Cox regression analysis was performed for survival and toxicity modelling. Results 495 patients were analysed (436 for toxicity). Median follow-up was 2.1 years (0–9.3 years). Median age was 11 years (0–69 years). 70.3% of patients were paediatric (<16y). Rhabdomyosarcoma (RMS) and Ewing sarcoma were the most common diagnoses (42.6% and 34.1%). 51.3% of treated patients were for Head & Neck (H&N) tumours, then Abdo/Pelvis (31.9%). The median PBT dose was 51Gy (range 20.4-76Gy), increasing with cohort age. At last known follow-up, 86.1% of all patients were alive, with 2- and 5-yr survival rates of 88.3% and 82.1% respectively. Equivalent local control rates were 88.8% and 82.6%. The highest mortality risk was for spindle cell sarcoma (60%). Mortality and local control were worse for adults (³25 years) than for the younger groups. The grade 3 toxicity rate was 12.6%, with median onset of 2.3 years. Most were in the H&N region in paediatric RMS patients. However, in relative terms, the adult cohort rate was higher (19.2%) than paediatric (14%) or TYA (5.6%), likely from higher doses received. Cataracts (30.5%) were most common, then musculoskeletal deformity (10.1%) and premature menopause (10.1%). Three paediatric patients (1-3 y at treatment) experienced secondary malignancy and 2 were found to have Li Fraumeni syndrome. Seven grade 4 toxicities occurred (1.6%), all in the H&N region and most in paediatric RMS patients. Six related to eyes (cataracts, retinopathy, scleral disorder) or ears (hearing impairment). Multivariate Cox regression analysis showed significance for increasing dose related to worse survival (p=0.006) and adult cohort grade 3 toxicity probability being higher than the paediatric cohort (p<0.001).
    Citation
    Hwang EJ, Gaito S, France A, Thwaites D, Ahern V, Indelicato D, et al. Non-CNS patient outcomes treated via the NHS proton overseas programme. Radiotherapy and Oncology. 2022 May;170:S36-S. PubMed PMID: WOS:000806759200038.
    Journal
    Radiotherapy and Oncology
    URI
    http://hdl.handle.net/10541/625480
    Type
    Meetings and Proceedings
    Language
    en
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.